Study Group: Pediatricians (US)
Council Members in this Study Group: 1695
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Jed Gorlin
Transfusion Service Director
HENNEPIN HEALTHCARE SYSTEM INC
Jed Gorlin, MD, MBA, is the Medical Director of the Memorial Blood Center of Minnesota and an Associate Professor of Laboratory Medicine and Pediatrics at the University of Minnesota. Dr. Gorlin is also the Transfusion Services Director at Hennepin County...
Michael BlaissPartner
ALLERGY & ASTHMA CAREMichael S. Blaiss, MD, is a Clinical Professor of Pediatrics and Medicine at University of Tennessee Health Sciences Center and in private practice at Allergy & Asthma Care in Memphis. Dr. Blaiss’s clinical focus is on allergies and has expertise in outcomes...
- Mark Vandewalker
Allergy Specialist and Partner
Allergy & Asthma Consultants Of The Ozarks LtdMark Vandewalker, MD, is an Allergy Specialist at Allergy and Asthma Consultants and he is the Medical Director at Clinical Research of the Ozarks in Missouri. Dr. Vandewalker is board-certified in Pediatric Allergy and has been practicing for almost...
- Steven Weinstein
Director
Allergy and Asthma Specialists Medical Group & Research CenterSteven Weinstein, MD, is the Director of Allergy and Asthma Specialists Medical Group and Research Center, California. He also holds an academic appointment as Clinical Professor of Allergy and Immunology in the Department of Pediatrics at the University...
- Richard Levy
Assistant Professor of Medicine and Pediatrics
RUSH UNIVERSITY MEDICAL CENTERRichard Levy, MD, is an Assistant Professor of Medicine and Pediatrics at Rush University Medical Center, and is a privately practicing adult and pediatric endocrinologist and diabetologist in Illinois. Dr. Levy has conducted research on diabetes and...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
FDA Poised to Damage Asthma Pharmacotherapy Advances
December 10, 2008
FDA: Long-Acting Asthma Drugs Increase Asthma Risks | online.wsj.com
The use of long-acting beta-agonists (LABAs) in the treatment of persistent asthma has become one of the most controversial issues of respiratory disease management during this decade. Both salmeterol and formoterol have been shown in numerous clinical trials of asthma to dramatically improve pulmonary function, symptoms scores, and need for rescue medication. However, some long-term safety studies have demonstrated increased risk of severe asthma exacerbations when these LABAs are used as monotherapy without concomitant inhaled steroid therapy. Based on this data, the FDA is considering the withdrawal of LABAs from the US market. I anticipate the FDA will come to their senses and appreciate the significant benefit that combination LABA/ICS therapy has in the vast majority of moderate and severe asthmatics for whom they are appropriately prescribed. In my opinion, cessation of LABA therapy for asthma would return us to asthma mortality rates not seen since the 1990s.
-
Will Xolair Become Obsolete in the Treatment of Allergies?
June 10, 2008
Investigational Anti-IgE Antibody Promising as Extracorporeal Allergy Therapy | www.medscape.com
This recent report characterizes a newly discovered anti-IgE monoclonal antibody (mAb12) which appears dramatically more potent than omalizumab (Xolair) in its ability to reduce systemic IgE levels. If further studies confirm this enhanced reduction of IgE and IgE-bearing cells, mAb12 has significant potential to replace omalizumab as effective anti-IgE therapy with just one dose, even in patients with very high initial levels of total IgE. The potential market share for such a treatment is enormous since at least 25% of the population suffers from Ige-mediated diseases such as allergic rhinitis, asthma, atopic eczema, and food allergy.
-
Impact of Symbicort on the U.S. Asthma Market
June 11, 2007
AstraZeneca Launches New Advance In Asthma Treatment - Symbicort Maintenance And Reliever Therapy (Symbicort SMART) | www.medicalnewstoday.com
Symbicort is AstraZeneca's answer to Advair, presently the number one combination ICS/LABA in the U.S. for treating moderate to severe asthma. Symbicort will not, however, have an indication for quick relief of bronchospasm as it does in many European countries. Nevertheless, Symbicort appears to be very well positioned to achieve significant market share, especially with the imminent release of the revised NIH guidelines which strongly emphasize long-term control of asthma.
-
Of Mice and Men: Revisiting the Hygiene Hypothesis
June 23, 2006
Wild Vs. Lab Rodent Comparison Supports Hygiene Hypothesis | medicalnewstoday.com
The "Hygiene Hypothesis" has gained recent favor to explain the dramatic increase in allergic conditions, as well as autoimmune disorders, especially in more industrialized countries that emphasize sanitation and stringent public health measures. The theory rests on lack of sufficient immunologic stimulation due to overly hygienic lifestyle thus encouraging allergic and possibly autoimmune processes to predominate. This hypothesis is supported by a recent study from Duke University comparing laboratory rodents living in an essentially "germ-free" environment to wild rodents naturally exposed to bacteria and parasites. The wild mice and rats have higher levels of certain antibodies which appear to afford protection from allergic and autoimmune disease. This putative mechanism may offer insight into the pathogenesis of allergy and autoimmunity in humans which could then be applied to developing preventive therapies to reduce the frequency of these chronic, debilitating disorders.
-
Is Roflumilast Blockbuster Therapy or a Ho-Hum Me-Too Drug?
June 16, 2006
Roflumilast Effective for Treating Mild-to-Moderate Asthma | www.medscape.com
Roflumilast is safe and effective in treating patients with mild-to-moderate asthma, according to a report in the May issue of the Annals of Allergy, Asthma, & Immunology. Altana and Pfizer are co-developing the experimental drug which is an oral phosphodiesterase type 4 (PDE-4) inhibitor with demonstrated anti-inflammatory and brochodilator activity and pharmacokinetics that allow once-daily dosing. Based on its mechanism of action, roflumilast can be expected to have similar efficacy to theophylline products but a more favorable side effect profile. Although current expert asthma guidelines continue to mention theophylline as second-line therapy, its relative market share has fallen dramatically over the last two decades with the present emphasis on inhaled corticosteroids and leukotriene modifiers. Assuming eventual European and FDA approval, roflumilast has potential to make a significant impact on the respiratory marketplace. How much depends greatly on marketing strategy by Altana and Pfizer as well as possible demonstration of superiority in future clinical trials.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Owner
- Professor
- Director